

ChemoCentryx, Inc.  
Form 8-K  
May 24, 2018

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 OR 15(d)**  
**of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): May 21, 2018**

**ChemoCentryx, Inc.**

**(Exact name of registrant as specified in its charter)**

**Delaware**  
**(State or other jurisdiction**

**of incorporation)**

**850 Maude Avenue, Mountain View, CA**

**001-35420**  
**(Commission**

**File Number)**

**94-3254365**  
**(IRS Employer**

**Identification No.)**

**94043**

(Address of Principal Executive Offices)

(Zip Code)

Registrant's telephone number, including area code: (650) 210-2900

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging Growth Company

Edgar Filing: ChemoCentryx, Inc. - Form 8-K

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 5.07. Submission of Matters to a Vote of Security Holders**

ChemoCentryx, Inc. (the Company) held its annual meeting of stockholders on May 21, 2018. The following is a brief description of each matter voted upon at the meeting and the number of votes cast for, withheld or against, the number of abstentions and the number of broker non-votes with respect to each matter, as applicable.

1. To elect the following Class I directors for a three-year term to expire at the 2021 annual meeting of stockholders:

| Director Name           | For        | Withheld  | Broker Non-Votes |
|-------------------------|------------|-----------|------------------|
| Thomas J. Schall, Ph.D. | 33,981,189 | 7,058,339 | 4,410,060        |
| Joseph M. Feczko, Ph.D. | 33,477,255 | 7,562,273 | 4,410,060        |

In accordance with the above results, above nominees were elected to serve as directors.

2. To ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2018:

| For        | Against | Abstain   | Broker Non-Votes |
|------------|---------|-----------|------------------|
| 38,649,600 | 62,155  | 6,737,833 | 0                |

In accordance with the above results, the selection of Ernst and Young LLP was approved.

3. To approve, on an advisory basis, the compensation of the Company's named executive officers as presented in the Proxy Statement:

| For        | Against | Abstain   | Broker Non-Votes |
|------------|---------|-----------|------------------|
| 33,962,440 | 277,243 | 6,799,845 | 4,410,060        |

In accordance with the above results, the compensation of the Company's named executive officers was approved.

4. To approve, on an advisory basis, the frequency of stockholder vote on the compensation of the Company's named executive officers as presented in the Proxy Statement:

| 3 Years    | 2 Years | 1 Year     | Abstain   |
|------------|---------|------------|-----------|
| 21,743,779 | 14,034  | 10,342,261 | 8,939,454 |

In accordance with the above results, the Company has determined that an advisory vote on the compensation of the Company's named executive officers will be conducted every three years, until the next advisory vote on the frequency of the advisory vote on the compensation of the Company's named executive officers.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CHEMOCENTRYX, INC.

Date: May 24, 2018

By: /s/ Susan M. Kanaya

Name: Susan M. Kanaya

Title: Executive Vice President, Chief Financial and  
Administrative Officer and Secretary